These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21697284)

  • 1. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
    Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
    Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
    Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
    Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
    Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
    Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
    Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
    Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
    Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
    Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
    Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
    [No Abstract]   [Full Text] [Related]  

  • 18. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
    Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
    J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
    Fujino T; Kobayashi Y; Suda K; Koga T; Nishino M; Ohara S; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    J Thorac Oncol; 2019 Oct; 14(10):1753-1765. PubMed ID: 31279006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
    Skaggs BJ; Gorre ME; Ryvkin A; Burgess MR; Xie Y; Han Y; Komisopoulou E; Brown LM; Loo JA; Landaw EM; Sawyers CL; Graeber TG
    Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19466-71. PubMed ID: 17164333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.